Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
Sponsored by University of Colorado, Denver
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Started 3 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Undergoing surveillance endoscopy for a diagnosis of non-dysplastic Barrett's esophagus (NDBE, based on last endoscopic procedure; patients with prior history of low-grade dysplasia/indefinite for dysplasia with NDBE at last endoscopy can be included)
- Barrett's esophagus (BE) length of at least M1
- English and Spanish speaking
- Able to comprehend and complete the consent form
- Age18-89 years
- Life-expectancy of at least 2 years Screening Population
- Undergoing endoscopy for screening of BE
- BE length of at least M1
- English and Spanish speaking
- Able to comprehend and complete the consent form
- Age 18-89 years
- Expected life-expectancy of at least 2 years Physicians -All participating sites will include physicians who are trained in the use of WATS3D and certified by the site PI. All endoscopists will need to complete a minimum of three cases to be eligible to participate in the study.
Exclusion Criteria
- BE patients undergoing surveillance or evaluation for endoscopic eradication therapy (EET) for prior diagnosis of BE related dysplasia or esophageal adenocarcinoma (EAC)
- Active erosive esophagitis with LA Grade B or higher
- Esophageal varices
- Prior history of EET
- Prior history of esophageal or gastric surgery, except for uncomplicated fundoplication
- Pregnancy Screening Population
- BE patients undergoing surveillance or evaluation for EET for prior diagnosis for BE-related dysplasia or EAC
- Active erosive esophagitis with LA Grade B or higher
- Esophageal varices
- Prior history of esophageal or gastric surgery, except for uncomplicated fundoplication
- Pregnancy